>latest-news

HOOKIPA Completes Enrollment For HIV Vaccine Trial

HOOKIPA finishes enrollment for its Phase 1b HB-500 HIV trial, with results expected in late 2025.

Breaking News

  • Jan 31, 2025

  • Simantini Singh Deo

HOOKIPA Completes Enrollment For HIV Vaccine Trial

HOOKIPA Pharma Inc. announced that the Phase 1b clinical trial measures patient safety alongside tolerance levels of HB-500, reaction potential, and immune response levels in HIV patients taking suppressive antiretroviral drugs. The clinical development phase of HB-500 for HIV treatment has reached enrollment completion at five United States centres where 30 patients received the investigational medicine. The Phase 1b investigation is divided into two groups where researchers assign participants to receive HB-500 or a placebo. Primary trial completion is set for the second half of 2025, while the first participant received drug administration on July 1, 2024. 

“Completing enrollment in our Phase 1b trial marks an important milestone for the HB-500 program and our strategic collaboration with Gilead and speaks to the focus on operational excellence at Hookipa,” commented Mark Winderlich, PhD, Chief Research & Development Officer of HOOKIPA.

Dan H. Barouch, M.D., Ph.D., Director of the Center of Vaccine and Virology Research, Beth Israel Deaconess Medical Center and Professor of Medicine, Harvard Medical School, said, “HB-500 is designed to induce robust and durable immunity and is a key component of a combination strategy for a potential functional cure of HIV using novel mechanisms aimed at driving viral suppression, durable immunity and eradication of the pro-viral reservoir.”

HOOKIPA conducts HIV program advancement by running Phase 1b clinical trials. The agreement provides Gilead with an exclusive right to continue program development after completion of the phase 1b clinical trial. The agreement between HOOKIPA and Gilead includes two distinct development programs. 

Ad
Advertisement